Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Trial of Gefapixant (MK-7264) for Acute Cough in Induced Viral Upper Respiratory Tract Infection
2017-000472-28Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute cough and Viral Upper Respiratory Infection comparing Gefapixant with Placebo (2 arms). Primary endpoint: Awake coughs per hour on Day 3 of treatment. Started Dec 2017; status: terminated.
02
Drugs
gefapixant
03
Conditions
acute coughViral Upper Respiratory Infection
Beyond the preview
Go deeper on 2017-000472-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000472-28.